- Topical Steroids
- Anti-viral drugs
Herpetic Keratitis Market was valued at USD 4,130 Million in 2022 and is poised to grow at a CAGR of 6.1% over 2023-2029. Herpetic keratitis is a form of keratitis caused by recurrent herpes simplex virus infection in the cornea, which begins with infection of the epithelial cells on the surface of the eye and retrograde infection of nerves serving the cornea and is characterized by swelling of the conjunctiva and eyelids. Based on the treatment type, the anti-viral segment is anticipated to dominate the herpetic keratitis market share over the forecast period. According to the World Health Organization, nearly 3.7 billion people under the age of 50 years have herpes simplex virus type 1 infection, and around 491 million people aged 15 to 49 years have herpes simplex virus type 2 infection. The increasing prevalence of chronic diseases, rapid advancements in the healthcare sector, and high adoption of techniques are the major herpetic keratitis market growth drivers, while the high cost of treatment could hinder the growth of the market. The increasing rate of mergers and acquisitions will act as an opportunity for geographical expansion of the market.
Fastest Growing Market
The rising focus on drug development, increasing demand for precision medicine, high adoption of home care settings, point-of-care diagnostics, and increasing investments in research and development activities are expected to drive the market revenue growth during the forecast period. For instance, in 2019 a randomized trial was conducted using topical corticosteroid in addition to oral antivirals for HSV keratitis recurrence prevention. Moreover, approved drugs such as Famciclovir, Valacyclovir, Acyclovir, and other drugs are being used in the treatment of HSV infection. However, the challenges associated with the diagnosis of the disease could act as a restraining factor.
The Herpetic Keratitis market was valued at USD 4,130 million in 2022 and is expected to grow at a 6.1% CAGR over the forecast period 2023 – 2029.
The increasing rate of mergers and acquisitions is the key opportunity for the Herpetic Keratitis market.
The increasing prevalence of skin conditions, rapid advancements in the healthcare sector, and high adoption of techniques are the growth drivers in the Herpetic Keratitis market.
Bausch & Lomb Incorporated, Vectans Pharma, GlaxoSmithKline plc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Jubilant Cadista, Mylan N.V., and Blistex are a few companies operating in the Herpetic Keratitis market.